Post by
forhandlaren on May 16, 2023 9:17am
Science Potential: Biomimicry
From Investor Presentation back in 2015 transformed into text:
Sirona's Glycoprotein program
- - Cosmetic Active Ingredients
- - - - Anti-aging
- - - - Protection & Regeration
- - - - - - Healing / wound care
- - - - - - Hypothermic protection
- - - - - - Sunscreen
- - - - - - Post-sunburn / radiotherapy
- - Adjuvants for biological material preservation
- - - - Cells
- - - - - - Stem cells
- - - - - - Islet cells
- - - - - - Platelets
- - - - - - Red blood cells
- - - - - - Adipocytes
- - - - Tissues
- - - - - - Skin explants
- - - - - - RHE
- - - - - - Cornea
- - - - Organs
- - - - - - Transplant
- - - - - - Renal Reperfusion
- - - - Living organisms
- - - - - - Vaccines
All we need now is that the management impress us with science transformation into very profitable deals. Where is the SGLT2 deals? Anyone?
Comment by
Turtle4 on May 16, 2023 10:01am
Management focuses on long-term profit. That is why they did not want a high upfront for 1067 with which they could drive other projects / research. Management would rather do that much much later, when they are profitable. So lets wait some years....
Comment by
navajojoe on May 16, 2023 12:09pm
This post has been removed in accordance with Community Policy
Comment by
navajojoe on May 18, 2023 8:31am
This post has been removed in accordance with Community Policy